Diagnostic yield and accuracy of different metabolic syndrome criteria in adult patients with epilepsy by Cabral, Lucas Scotta et al.
September 2017 | Volume 8 | Article 4601
Original research
published: 01 September 2017
doi: 10.3389/fneur.2017.00460
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Fernando Cendes, 
Universidade Estadual 
de Campinas, Brazil
Reviewed by: 
Luiz Eduardo Betting, 
Universidade Estadual Paulista Júlio 
Mesquita Filho, Brazil  
Marco Mula, 
St George’s, University of London, 
United Kingdom
*Correspondence:
Marino Muxfeldt Bianchin  
mbianchin@hcpa.edu.br
Specialty section: 
This article was submitted 
to Epilepsy, 
a section of the journal 
Frontiers in Neurology
Received: 17 March 2017
Accepted: 18 August 2017
Published: 01 September 2017
Citation: 
Cabral LS, Cherubini PA, 
de Oliveira MA, Bianchini L, 
Torres CM and Bianchin MM (2017) 
Diagnostic Yield and Accuracy of 
Different Metabolic Syndrome Criteria 
in Adult Patients with Epilepsy. 
Front. Neurol. 8:460. 
doi: 10.3389/fneur.2017.00460
Diagnostic Yield and accuracy of 
Different Metabolic syndrome criteria
in adult Patients with epilepsy
 
Lucas Scotta Cabral1,2,3, Pedro Abrahim Cherubini2,3, Marina Amaral de Oliveira2,  
Larissa Bianchini 2, Carolina Machado Torres1,2,3,4 and Marino Muxfeldt Bianchin1,2,3,4*
1 Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 
2 Basic Research and Advanced Investigations in Neurology (BRAIN), Experimental Research Centre, Hospital de Clínicas 
de Porto Alegre, Porto Alegre, Brazil, 3 Neurology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 
4 Centro de Tratamento de Epilepsia Refratária (CETER), Department of Neurology, Hospital de Clínicas de Porto Alegre, 
Porto Alegre, Brazil
introduction: Metabolic syndrome (MetS) is an emergent problem among patients with 
epilepsy. Here, we evaluate and compare the diagnostic yield and accuracy of different 
MetS criteria among adult patients with epilepsy to further explore the best strategy for 
diagnosis of MetS among patients with epilepsy.
Materials and methods: Ninety-five epileptic adults from a tertiary epilepsy reference 
center were prospectively recruited over 22 weeks in a cross-sectional study. MetS was 
defined according to five international criteria used for the diagnosis of the condition 
[ATP3, American Association of Clinical Endocrinologists (AACE), International Diabetes 
Federation (IDF), AHA/NHLBI, and harmonized criteria]. Sensitivity, specificity, positive 
and negative predictive values (NPVs), and area under the receiver operating character-
istic curve (ROC) curve were estimated for each criterion.
results: In our sample, adult patients with epilepsy showed a high prevalence of 
obesity, hypertension, and diabetes. However, the prevalence of MetS was significantly 
different according to each criterion used, ranging from 33.7%, as defined by AACE, 
to 49.4%, as defined by the harmonized criteria (p < 0.005). IDF criteria showed the 
highest sensitivity [S = 95.5% (95% CI 84.5–99.4), p < 0.05] and AACE criteria showed 
the lowest sensitivity and NPV [S = 68.2% (95% CI 52.4–81.4), p < 0.05; NPV = 75.8% 
(95% CI 62.3–86.1), p < 0.05]. ROC curve for all criteria studied showed that area under 
curve (AUC) for IDF criterion was 0.966, and it was not different from AUC of harmonized 
criterion (p =  0.092) that was used as reference. On the other hand, the use of the 
other three criteria for MetS resulted in significantly lower performance, with AUC for 
AHA/NHLBI = 0.920 (p = 0.0147), NCEP/ATP3 = 0.898 (p = 0.0067), AACE = 0.830 
(p = 0.00059).
conclusion: Our findings suggest that MetS might be highly prevalent among adult 
patients with epilepsy. Despite significant variations in the yield of different criteria, the 
harmonized definition produced the highest prevalence rates and perhaps should be 
preferred. Correct evaluation of these patients might improve the rates of detection of 
MetS and foster primary prevention of cardiovascular events in this population.
Keywords: metabolic syndrome, comorbidities in epilepsy, general medical conditions, risk factors, cardiovascular 
risk
TaBle 1 | Summary of published studies evaluating metabolic syndrome (MetS) occurrence in epilepsy patients.
reference study design Patients criteria for 
Mets
Mets occurence comments
Pylvänen et al. (10) Case–control 51 epileptic adults 45 healthy 
controls
ATP3 17.6% All cases in monotherapy with  
valproate
Kim and Lee (11) Cross-sectional 54 adult women with epilepsy AHA/NHLBI 41.7% in patients on valproate Small number of patients in each 
antiepileptic drug group5.3% in patients on carbamazepine
Verrotti et al. (12) Cohort 114 children and adolescents 
with epilepsy
“Age-adapted” 
ATP3
43.5% in obese patients Follow-up: 24 months
Overall (obese + non-obese): 17.5% Results valid for overweight or  
obese
Fang et al. (13) Case–control 36 epileptic adults, 26 obese 
non-epileptic controls
AHA/NHLBI 47.2% in epileptic patients, 32.1% in 
controls
All cases in monotherapy with  
valproate
Rakitin et al. (15) Cross-sectional 213 epileptic adults ATP3 20.3% in patients on valproate Imbalance of severe physical or  
mental disability between groups40% in patients on carbamazepine
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inTrODUcTiOn
Epilepsy is a common serious chronic neurologic disorder, 
affecting about 50 million people worldwide (1). Data from 
2000 estimated the world’s epilepsy-related burden of disease as 
6,223,000 disability-adjusted life years (2), and ILAE/IBE/WHO 
Global Campaign against Epilepsy reaffirmed the prediction 
that the global burden of this disease will rise 14.7% in the next 
decade (3). Although epidemiological studies have pointed out 
that treatment success rates, public health policies, education, 
and psychosocial issues are key factors in Health-Related Quality 
of Life of patients with epilepsy, they have hardly addressed the 
impact of some common general medical conditions in patients 
with epilepsy (4). There is, indeed, growing concern regarding 
comorbidity management in epilepsy and the overall impact that 
they play in the global quality of life of patients with epilepsy.
Cardiovascular disease (CVD) has become the leading cause 
of death and has lifetime prevalence greater than 70% in western 
civilizations (5). In a cohort of 9,061 adult patients hospitalized 
due to epilepsy, estimated coronary heart disease mortality was 
2.5 times the predicted rate; even greater rates were observed 
regarding stroke (6). A cross-sectional population-based study 
showed 34% increase in risk of coronary heart disease and 68% 
increase in risk of fatal CVD among patients with epilepsy (7). 
Also, a Swedish case–control study linked epilepsy to a sig-
nificantly higher incidence of myocardial infarction and worse 
cardiovascular outcomes (8).
Among the clinical tools for prediction of future CVD, the 
concept of metabolic syndrome (MetS) is well accepted. MetS is 
defined as a cluster of metabolic risk factors that include central 
obesity, dyslipidemia, insulin resistance, and/or glucose intoler-
ance, and abnormally high blood pressure, in variable associations 
that increases the risk to develop CVD and diabetes (9). The 
occurrence and relevance of MetS in patients with epilepsy has 
been gaining growing emphasis in the neurological literature 
(10–15). These studies are resumed in Table 1, and they focused 
mainly on prevalence and metabolic aspects of MetS, but the 
definitions used were heterogeneous and data not readily compa-
rable. In fact, various medical societies had published their own 
criteria for the MetS diagnosis, but how these criteria correlate, 
and more importantly, which is the one that best fits the epileptic 
population, is currently unknown. The objective of our study is to 
report the prevalence of MetS in patients with epilepsy in a cohort 
of an outpatient clinic of a tertiary hospital and evaluate diagnostic 
yield and accuracy of five different internationally accepted MetS 
criteria in these patients. We hope our work can drive attention 
to an underestimated health problem in patients with epilepsy, 
perhaps helping to improve care of these patients in near future.
MaTerials anD MeThODs
This study aimed to determine the prevalence of MetS in a cohort 
of patients with epilepsy in an outpatient clinic of a tertiary hos-
pital and to determine the general and specific performance of 
five international criteria used for the diagnosis of MetS. For this, 
we investigated National Cholesterol Education Program’s Adult 
Treatment Panel III (NCEP ATP3) (16), American Association 
of Clinical Endocrinologists (AACE) (17), American Heart 
Association/National Heart, Lung and Blood Institute (AHA/
NHLBI) (18), International Diabetes Federation (IDF) (19), and 
the harmonized criteria (IDF/NHLBI/AHA/WHF/IAS/IASO) 
(20). Harmonized criterion was used as gold standard to compare 
other criteria. Each criterion is composed of five specific subsets 
of criteria [obesity, high-density lipoprotein (HDL) cholesterol, 
triglycerides, dysglycemia, hypertension], each one with variable 
cutoffs. Table 2 presents a comparative view of components of five 
internationally accepted criteria for MetS diagnosis used in this 
study. Table 3 is revising cutoff values for waist circumference, 
by ethnic group, for the definition of central obesity in the IDF 
criteria. Table 4 is revising the cutoff values for waist circumfer-
ence, by ethnic group, for the definition of central obesity in the 
harmonized criteria for comparison (IDF/NHLBI/AHA/WHF/
IAS/IASO, 2009).
study Design and Patient Population
A cross-sectional, consecutive, single-center study was carried out at 
the Epilepsy Outpatient Clinic, Hospital de Clínicas de Porto Alegre. 
This is a tertiary hospital located in the Southern region of Brazil. 
Porto Alegre is the capital of Rio Grande do Sul State, with a popula-
tion of 1,416,735 individuals distributed in an area of 496.8 km2. A 
large fraction of the State population consists of Caucasian European 
immigrants, e.g., German, Italian, and Portuguese ones.
TaBle 2 | Comparative view of components of five accepted criteria for metabolic syndrome diagnosis.
criteria
aTP3 2002 american association 
of clinical 
endocrinologists 2003
aha/nhlBi 2005 international Diabetes 
Federation (iDF) 2005
iDF/nhlBi/aha/WhF/ias/
iasO
(harmonized) 2009
Reference National Cholesterol 
Education Program (NCEP) 
Expert Panel on Detection, 
Evaluation and Treatment 
of High Blood Cholesterol 
in Adults (Adult Treatment 
Panel III) (16)
Einhorn et al. (17) Grundy et al. (18) Alberti et al. (19) Alberti et al. (20)
Conditions for 
diagnosis
Three or more High risk of insulin 
resistance OR BMI 
≥25 kg/m2 OR ↑waist 
circumference (males: 
≥102 cm/females: 
≥88 cm) PLUS two or 
more
Three or more Increased waist 
circumference [according 
to ethnic group—See Ref. 
(19)] PLUS two or more
Three or more
component
Obesity Waist circumference males: 
≥102 cm, females: ≥88 cm
– Waist circumference 
males: ≥102 cm, females: 
≥88 cm
– Increased waist circumference 
[according to ethnic group—
See Ref. (20)]
Low high-
density 
lipoprotein 
cholesterol
Males: <40 mg/dL, females: 
<50 mg/dL
Males: <40 mg/dL, 
females: <50 mg/dL
Males: <40 mg/dL, 
females: <50 mg/dL OR 
on specific antilipemic 
drug(s)
Males: <40 mg/dL, 
females: <50 mg/dL
Males: <40 mg/dL, females: 
<50 mg/dL OR on specific 
antilipemic drug(s)
Elevated 
triglycerides
≥150 mg/dL ≥150 mg/dL ≥150 mg/dL OR on 
specific antilipemic drug(s)
≥150 mg/dL ≥150 mg/dL OR on specific 
antilipemic drug(s)
Dysglycemia FBG ≥ 110 mg/dL FBG ≥110 mg/dL OR 2 h 
oral glucose tolerance test 
≥140 mg/dL
FBG ≥100 mg/dL OR on 
antihyperglycemic drug(s)
FBG ≥ 100 mg/dL OR 
previous T2DM diagnosis
FBG ≥ 100 mg/dL OR on 
antihyperglycemic drug(s)
High blood 
pressure
≥130/85 mmHg OR on 
antihypertensive drug(s)
≥130/85 mmHg ≥130/85 mmHg OR on 
antihypertensive drug(s)
≥130/85 mmHg OR 
on antihypertensive 
drug(s) WITH previous 
hypertension diagnosis
130/85 mmHg OR on 
antihypertensive drug(s) WITH 
previous hypertension diagnosis
TaBle 3 | Cutoff values for waist circumference, by ethnic group, for the 
definition of central obesity in the International Diabetes Federation criteria  
(2005) (19).
ethnic group Waist circumference cutoff
europoids
Males ≥94 cm
Females ≥80 cm
south asians and chineses
Males ≥90 cm
Females ≥80 cm
Japaneses
Males ≥85 cm
Females ≥90 cm
South and Central Americans Use South Asian data when local cutoffs 
unknown
Sub-Saharan Africans Use Europoids data when local cutoffs 
unknown
Mediterranean and Arab populations Use Europoids data when local cutoffs 
unknown
TaBle 4 | Cutoff values for waist circumference, by ethnic group, for the 
definition of central obesity in the harmonized criteria (International Diabetes 
Federation/NHLBI/AHA/WHF/IAS/IASO, 2009) (20).
Population Waist circumference cutoff
Males (cm) Females (cm)
Europoid ≥94 ≥80
Caucasian ≥94 (high risk) ≥80 (high risk)
≥102 (even higher risk) ≥88 (even higher)
United States of America ≥102 ≥88
Canada ≥102 ≥88
European ≥102 ≥88
Asia (including Japan) ≥90 ≥80
Asia (excluding Japan) ≥90 ≥80
Japaneses ≥85 ≥90
Chineses ≥85 ≥80
Middle East, Mediterranean ≥94 ≥80
Sub-Saharan Africa ≥94 ≥80
Central and South America ≥90 ≥80
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Patients were eligible if older than 18 years of age, received a 
definite diagnosis of epilepsy, attended to the center for 6 months 
or more and had used antiepileptic drugs (AEDs) for at least 1 year. 
We excluded patients with major adverse cardiovascular events 
(myocardial infarction, ischemic stroke, revascularization proce-
dures) since, by definition, these patients had high cardiovascular 
risk (21). Patients with cerebrovascular disorders presumed to 
be of atherosclerotic origin (i.e., asymptomatic carotid stenosis) 
were also excluded. Other kinds of cerebrovascular disorders 
(e.g., arteriovenous malformations, aneurysms) were included. 
The inability to obtain accurate biometrical data was also an exclu-
sion criterion. Personal demographic data (age, sex, ethnicity, dis-
ability) were derived from medical records, and when unavailable, 
from clinical interview with patients or their proxies. Electronic 
medical records were reviewed on a weekly basis. Subjects were 
recruited by phone or personal contact before routine medical 
visits. The study was approved by the Ethics Committee of our 
Institutional Review Board (GPPG-HCPA; Approval Protocol 
Number: 110311) and is fully compliant with the Declaration 
of Helsinki. All individuals enrolled in the study, or their legal 
proxies, gave written informed consent prior to their inclusion, 
and were free to withdraw such consent at any given time.
Variables and clinical assessments
All clinical assessments were performed as recommended else-
where (20, 22, 23). After data collection, the investigators were 
blinded to the results and then received anonymous data to clas-
sify the patients according to the five MetS criteria. Diagnostic 
yield and accuracy parameters were estimated for each criterion. 
Epilepsy syndromes were classified according to ILAE recom-
mendations (24, 25). Epilepsy cause, treatment, control, and 
duration were also investigated. Electronic medical records were 
reviewed for EEGs and neuroimaging studies. Seizures were 
deemed controlled if the current interictal period was greater 
than 1  year. Population-specific thresholds for increased waist 
circumference were set at 80 cm for females and 90 cm for males 
(19). Anthropometric measuring devices and sphygmomanom-
eters were checked biweekly and calibrated as needed. Regular 
physical exercise was defined as at least 12 MET-hours per 
week (26). All blood samples were obtained at 8:00 a.m. after 
an overnight fasting, and handled independently by the central 
laboratory. Missing data were handled by deleting the given case 
from final analysis.
sample size Determination and statistical 
analysis
We used as gold standard the harmonized criteria to perform 
diagnostic of MetS in patients with epilepsy (IDF/NHLBI/
AHA/WHF/IAS/IASO) (20). We hypothesized that at least one 
criteria would show significantly different sensitivity, specificity, 
or predictive values from harmonized criteria. Based on data 
from previous reports, we estimated a sample size of at least 88 
participants to reject the null hypothesis with 0.8 probability 
(27). Categorical data were expressed as counts (%), and con-
tinuous data as mean (±SD). Since MetS is a clinical diagnosis, 
the harmonized criterion was elected as the reference standard, 
in accordance to previous recommendations (28); unadjusted 
and adjusted sensitivities, specificities, and predictive values 
were plotted using the random effects model. Specific report-
ing are in agreement with Standards for Reporting Diagnostic 
Accuracy (STARD) statement when applicable (29). The area 
under the receiver operating characteristic curve (ROC curve) 
was estimated to further compare MetS criteria other than 
harmonized criteria (30). Cohen’s kappa or McNemar test was 
used to evaluate concordance of different MetS criteria with 
the harmonized reference, when appropriate. Other categorical 
variables were compared using the chi-square or Fisher’s exact 
test, and continuous data were compared using one-way ANOVA 
or the Kruskal–Wallis test (with subsequent post hoc tests). All 
tests were two-sided and all statistics were performed using SPSS 
Statistics 19.0 and MedCalc 16.4. A p-value less than 0.05 was 
considered significant.
resUlTs
A total of 752 patients with epilepsy attended the outpatient 
clinic over a period of 22 weeks (from February to July 2011). 
Ninety-five patients fulfilled the inclusion criteria and agreed 
to participate in the study. In five cases, the laboratory samples 
were not handled properly, so part of their data were unavailable 
for analysis. One patient withdrew consent to the use of his bio-
chemical data, totaling 89 patients available for MetS evaluation 
(Figure 1). No adverse effects were noted during data collection. 
Clinical and demographic characteristics of the patients are 
presented in Table 5.
epilepsy-related Features
In our sample, 88.4% of patients presented focal epilepsy, with a 
mean duration of approximately 25 years. A composite of unknown 
causes (48.4%), infections (17.9%), and cerebrovascular disorders 
(16.8%) accounted for most causes of epilepsy. Neurocysticercosis 
(n =  12) and pneumococcal meningitis (n =  2) were the most 
common infectious causes. In line with the predominance of focal 
epilepsy, more individuals were on carbamazepine than on valp-
roic acid (70.1 vs 15.8%, p = 0.02). About half of the patients were 
seizure-free at the study time. Patients on monotherapy showed 
statistical trend for seizure control when compared with patients 
on polytherapy (55.8 vs 37.2%, p = 0.055).
general Medical conditions
The average occurrence of general medical and psychiatric 
comorbidities was 50% each. Hypertension (40%) was signifi-
cantly more prevalent than any other comorbidity. Diabetes was 
detected in 8 (8.4%) patients, and all of them were in the MetS 
group, as expected. The use of antihypertensive (45.5 vs 15.6%, 
p =  0.003), antidiabetics (11.4 vs 0%, p =  0.026), and statins 
(34.1 vs 4.4%, p < 0.001) were more common in the MetS group. 
Overall, psychiatric comorbidities were observed in 41 (43.2%) 
of patients, with no differences between patients with MetS and 
without MetS (52.3 vs 33.3%, p = 0.088).
Diagnostic Yield and accuracy
The reference criterion, the harmonized criterion, identified 
44 individuals with MetS. MetS prevalence ranged from 33.7% 
FigUre 1 | Flowcharts of the selection of patients and classification according with different metabolic syndrome (MetS) criteria.
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(AACE) to 49.4% (harmonized criterion), a statistically signifi-
cant difference (p < 0.005) (Table 6). It is of note that even ATP3 
or AHA/NHLBI criteria also were unable to identify 9 and 7 
MetS cases each, and so disclosed significantly lower prevalence 
of MetS than the reference harmonized criterion (39.3 vs 49.4%, 
p < 0.005 and 41.6 vs 49.4%, p < 0.02, respectively).
Figure 2 is showing tabulation and graphical plots of sensi-
tivities and specificities for different criteria analyzed. Regarding 
sensitivity, the IDF criterion showed the highest value [S = 95.5% 
(95% CI) 84.5–99.4%], and all criteria showed significantly lower 
sensitivities when compared to the harmonized one. On further 
analysis, the IDF criterion also showed a significantly higher 
sensitivity than the AACE criterion (95.5 vs 68.2%, p <  0.05). 
Unadjusted analysis showed that both the ATP3 (79.5%) and 
AHA/NHLBI (84.1%) criteria had significantly higher sensitivi-
ties than the AACE criterion (68.2%), but this significance was 
lost after adjustment. All criteria showed similarly high specifici-
ties and positive predictive values (p > 0.5).
The negative predictive value (NPV) of IDF (94.7%) out-
performed all other definitions (p  <  0.05). IDF and AHA/
NHLBI definition also showed higher NPV than AACE (95.7 
and 85.8 vs 75.8%, p < 0.05), but again, significance was lost 
after adjustment. In terms of overall performance of the defini-
tions, the area under the ROC curve (AUC) varied from 0.83 
TaBle 5 | Demographic and clinical characteristics of the patients.
all subjects (n = 95)a Patients evaluated with harmonized criteria (n = 89)a p-Value
With Mets (n = 44) Without Mets (n = 45)
Age (years) 45.9 ± 15.3 50.41 + 15.4 43.04 ± 14.3 0.022
Sex ratio (M/F) 35/60 16/28 16/29 0.937
Caucasians 86 (90.5%) 40 (90.5%) 41 (91.1%) 0.973
Current smoker 15 (15.8%) 8 (18.2%) 7 (15.6%) 0.784
Regular alcohol intake 24 (25.3%) 13 (29.5%) 9 (20.0%) 0.334
Regular physical exercise 37 (38.9%) 21 (47.7%) 14 (31.1%) 0.132
Major epileptic syndrome
Generalized 8 (8.4%) 5 (11.4%) 3 (6.7%)
Focal 84 (88.4%) 38 (86.4%) 40 (88.9%)
Unknown 3 (3.2%) 1 (2.2%) 2 (4.4%) 0.646
epilepsy etiology
Unknown 46 (48.4%) 22 (50.0%) 23 (51.1%)
CNS infections 17 (17.9%) 6 (13.6%) 10 (22.2%)
Cerebrovascular diseasesb 16 (16.8%) 10 (22.7%) 5 (11.1%)
Brain trauma 5 (5.3%) 2 (4.5%) 2 (4.4%)
Mesial hippocampal sclerosis 5 (5.3%) 2 (4.5%) 2 (4.4%)
CNS neoplasms 2 (2.1%) 1 (2.3%) 1 (2.2%)
Other disordersc 4 (4.2%) 1 (2.3%) 2 (4.4%) 0.807
Epilepsy duration (years) 25.5 ± 16.2 26.4 + 17.1 25.3 ± 15.5 0.766
Seizure freedom 45 (47.4%) 20 (45.5%) 22 (48.5%) 0.833
current pharmacotherapy
Monotherapy 52 (54.7%) 26 (59.1%) 23 (51.1%) 0.525
Time on antiepileptic drug (aeD)
>120 months 75 (78.9%) 35 (79.5%) 36 (80.0%) 0.957
specific aeD info
On carbamazepine 67 (70.5%) 27 (61.4%) 34 (75.6%) 0.175
Mean dose (mg/day) 900.0 ± 371.3 940.8 ± 322.5 879.4 ± 416/2 0.531
On valproic acid 15 (15.8%) 8 (18.2%) 7 (15.6%) 0.784
Mean dose (mg/day) 983.3 ± 258.2 968.8 ± 160.2 1,000.0 ± 353.5 0.825
On phenytoin 13 (13.7%) 4 (9.1%) 9 (20.0%) 0.230
Mean dose (mg/day) 303.9 ± 43.1 275.0 ± 50.0 316.7 ± 35.3 0.110
On phenobarbital 26 (27.4%) 10 (43.5%) 13 (56.5%) 0.629
Mean dose (mg/day) 130 ± 54 150.0 ± 75 123.1 ± 38.8 0.282
On other AEDd 8 (8.4%) 5 (11.4%) 3 (6.7%) 0.048
On any benzodiazepine 21 (22.1) 11 (25.0%) 10 (22.2%) 0.807
Other medical disorders
Any chronic disordere 45 (47.4%) 26 (59.1%) 18 (40%) 0.091
On antihypertensives 28 (29.5%) 20 (45.5%) 7 (15/6%) 0.003
On antidiabetics 5 (5.3%) 5 (11.4%) 0 (0%) 0.026
On statins 17 (17.9%) 15 (34.1%) 2 (4.4%) <0.001
Psychiatric comorbidities
Any psychiatric disorder 41 (43.2%) 23 (52.3%) 15 (33.3%) 0.088
CNS, central nervous system; AED, antiepileptic drug(s).
aLaboratory data unavailable for six patients.
bExcluding ischemic stroke of definite or presumed atherosclerotic etiology.
cSingle cases of cerebral lipomatosis, toluene-induced brain damage, non-ketotic hyperhyperglucemia.
dLamotrigine, oxcarbazepine, primidone, topiramate.
eExcluding hypertension, elevated fasting glucose, impaired glucose tolerance, dyslipidemia, obesity, smoking and alcohol abuse.
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(0.73–0.92) in the AACE definition to 0.96 (0.86–1.0) in the 
IDF definition. Further exploratory analysis showed that when 
diabetic patients were not excluded in the AACE definition 
(as default), the NPV overlapped with all others (p =  0.65). 
The inter-definition agreement was more robust for the IDF 
criterion, but remained significant for all definitions, as can be 
seen on Table 7. Figure 3 is showing ROC curve for all criteria 
studied, and we performed a statistical analysis comparing all 
AUC with the AUC for harmonized criterion used as reference. 
This analysis showed that AUC for IDF criterion was 0.966, 
and it was not different from AUC of harmonized criterion 
(p = 0.092). On the other hand, the use of the other three criteria 
for MetS resulted in significantly lower performance, with AUC 
for AHA/NHLBI =  0.920 (p =  0.0147), NCEP/ATP3 =  0.898 
TaBle 7 | Inter-definition agreement for metabolic syndrome diagnosis.
criteria Kappa p-Value
ATP3 2002 0.797 <0.001a
American Association of Clinical Endocrinologists 2003 0.662 <0.001a
International Diabetes Federation 2005 0.933 <0.001a
AHA/NHLBI 2005 0.842 <0.001a
aAll comparisons with harmonized criteria.
FigUre 2 | Tabulation and graphical plot of sensitivities and specificities.
TaBle 6 | Diagnostic accuracy of different metabolic syndrome criteria in 89 patients with epilepsy.
accuracy, % (95% ci)
criteria TP FP Fn Tn sensitivity specificity PPV nPV aUc (95% ci)
ATP3 2002 35 (39.3)a 0 9 45 79.5 (64.7–90.2)c 100 (92.1–100) 98.6 (88.2–100) 82.7 (75.9–83.6)c 0.89 (0.82–0.97)
American Association of Clinical 
Endocrinologists 2003
30 (33.7)a 1 14 44 68.2 (52.4–81.4)c 97.8 (88.2–99.9) 96.7 (83.3–99.9) 75.8 (62.3–86.1)c 0.83 (0.73–0.92)
International Diabetes Federation 
2005
42 (47.2) 1 2 44 95.5 (84.5–99.4) 97.8 (88.2–99.9) 96.6 (87.7–99.9) 95.7 (85.2–99.5) 0.96 (0.86–1.0)
AHA/NHLBI 2005 37 (41.6)b 0 7 45 84.1 (69.9–93.4)c 100 (92.1–100) 100 (90.5–100) 86.6 (74.2–94.4)c 0.92 (0.85–0.98)
Harmonized 44 (49.4) – – – – – – – –
TP, true positives; FP, false positives; FN, false negatives; TN, true negatives; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUC, area under 
the receiver operating characteristic curve.
ap < 0.005.
bp < 0.02.
cp < 0.05.
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(p = 0.0067), AACE = 0.830 (p = 0.00059) when compared with 
harmonized criterion.
Mets individual components analysis
In our patients, the prevalence of obesity ranged from 53.9% 
(according to ATP3 and AHA/NHLBI criterion) to 79.8% (accord-
ing to the IDF criterion) (p < 0.001). Fewer individuals fulfilled 
the ATP3 dysglycemia criterion (12.4%, p <  0.001) and AACE 
(16.9%, p < 0.02) when compared with the harmonized defini-
tion (30.3%) (Table 8). The oral glucose tolerance test (OGTT) 
was necessary to correctly classify six patients, but it changed 
AACE classification in only three patients. Additional analyses of 
selected anthropometric and biochemical are shown in Table 9.
DiscUssiOn
In this study, we estimated the prevalence of MetS according 
to five internationally accepted criteria and their diagnostic 
performance in a cohort of adult patients with epilepsy without 
previous major cardiovascular events. In these patients, we 
observed high rates of MetS, obesity, hypertension, and diabetes. 
Also, the AUC using IDF criterion was not different from AUC 
of harmonized criterion. On the other hand, the use of the other 
evaluated criteria for MetS resulted in significantly lower diag-
nostic performance. Thus, our findings suggest that the use of the 
harmonized or IDF criteria might result in higher detection rates 
of MetS in adult patients with epilepsy.
The present data showed that MetS prevalence varied between 
33.7 and 49.4%, and it is variable according to the used criteria. 
Unadjusted prevalence in unselected adults vary between 34.8 
and 45.9% (19). Neurologic publications found rates like 11.1% in 
a selected population of Korean women (11), 29.5% in an Indian 
population with higher valproate exposure and adapted ATP-3 
criteria (14), and up to 43.5% in a highly selected cohort of over-
weight youngster using valproate evaluated by another adaptation 
of ATP3 criteria (12). As one struggles to draw valid conclusions 
when summarizing these studies, the strengths of our work start 
to become clear. First, it provides a common framework for com-
parison of different findings by diverse criteria and their inherent 
relationship. In fact, as far as we can track, the IDF and AACE 
definitions had not been formally applied in medical studies in 
patients with epilepsy, yet, and perhaps our data are able support 
the use of IDF definition better than AACE definition. Second, 
most patients included in our study were adults with focal epi-
lepsies and most patients were using sodium channel inhibitors. 
Accordingly, TIGER team reports in the VA study showed that 
TaBle 8 | Individual component prevalence analysis for different metabolic syndrome (MetS) criteria.
criteria for Mets
aTP3, 2002 international Diabetes 
Federation, 2005
american association of clinical 
endocrinologists, 2003
aha/nhlBi, 2005 harmonized, 2009
specific component
Obesity 48 (53.9%)a 71 (79.8%) 62 (69.7%) 48 (53.9%)a 70 (78.7%)
HDL-C 38 (42.7%) 38 (42.7%) 38 (42.7%) 38 (42.7%) 38 (42.7%)
Triglycerides 31 (34.8%) 31 (34.8%) 31 (34.8%) 31 (34.8%) 31 (34.8%)
Dysglycemia 11 (12.4%)a 28 (31.5%) 15 (16.9%)b 27 (30.3%) 27 (30.3%)
Hypertension 63 (70.8%) 62 (69.7%) 58 (65.2%) 63 (70.8%) 62 (69.7%)
Partial analysis of metabolic syndrome diagnosis
No component 12 (13.5%) 9 (10.1%) 9 (10.1%) 11 (12.4%) 11 (12.4%)
One component 22 (24.7%)c 12 (13.5%) 16 (18%) 21 (23.6%)c 10 (11.2%)
Two components 20 (22.5%) 25 (28.1%) 26 (29.2%) 20 (22.5%) 24 (27%)
Mean number of components 2.13 ± 1.43a 2.57 ± 1.5 2.28 ± 1.34a 2.32 ± 1.58a 2.56 ± 1.52
HDL-C, high-density lipoprotein cholesterol.
All comparisons related to the harmonized criteria.
ap < 0.001.
bp < 0.02.
cp < 0.005.
FigUre 3 | Receiver operating characteristic curve for all criteria studied. 
Statistical analysis comparing all area under curve (AUC) with the AUC for 
harmonized criterion, used as reference. AUC for International Diabetes 
Federation (IDF) criterion was 0.966, and it was not different from AUC of 
harmonized criterion (p = 0.092). On the other hand, the use of the other 
three criteria for MetS resulted in significantly lower performance, with AUC 
for AHA/NHLBI = 0.920 (p = 0.0147), NCEP/ATP3 = 0.898 (p = 0.0067), 
American Association of Clinical Endocrinologists (AACE) = 0.830 
(p = 0.00059) when compared with harmonized criterion.
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Our diagnostic accuracy analysis showed better performance 
of harmonized or IDF criteria for patients with epilepsy. In this 
venue, some observations are possible and need to be pointed 
out. The sensitivities observed varied from 68 to 95%; this implies 
that for each four given patients with MetS screened with the har-
monized or IDF definitions, one would be missed by the AACE 
criteria. Besides that, in our study, IDF criteria showed the highest 
sensitivity and inter-definition agreement with the harmonized 
criteria. This is possibly related to the tighter cut offs for waist 
circumference (32), and a closer look at our population showed 
higher than expected values, especially in females. Lofgren and 
coworkers also found that epileptic women had higher risk of obe-
sity, and that sedentarism and long-term use of AED were linked 
to higher BMI (33). Furthermore, the AACE criterion showed 
a low NPV (about 75%) in our population, which may hinder 
its clinical applicability. One possible explanation is the fact the 
AACE does not accept the coexistence of MetS and diabetes (17); 
the exploratory analysis showed above corroborates this proposi-
tion, and points out that OGTT adds little to the diagnosis. Taken 
together, these findings suggest that in patients with epilepsy, the 
AACE criterion should be used with more caution, especially in 
females, while the harmonized (and secondarily IDF) might be 
more suitable for the diagnosis of MetS.
The prevalence of MetS in Brazilian population is variable, 
and it has been underreported. In a recent systematic review, 
de Carvalho Vidigal et al. revised 10 cross sectional studies that 
reported a prevalence of MetS of 29.6%, ranging from 14.9 to 
65.3% (34). In this study, the highest prevalence of MetS (65.3%) 
was found in an indigenous population, whereas the lowest 
prevalence of MS (14.9%) was reported in a rural area. The most 
frequent MetS components were low HDL-cholesterol (59.3%) 
and hypertension (52.5%). The two studies that evaluated urban 
population closer to our sample showed a prevalence of MetS 
that was variable from 35.9 to 43.2%. Silva et  al. evaluated the 
prevalence of MetS in 287 adults from the urban region of the 
up to 80% of those who had epilepsy at age 65 or greater were on 
a similar therapeutic regimen, and that remained stable (31), an 
observation in line with our findings. Third, the underrepresenta-
tion of valproic acid in the sample helps to minimize potential 
bias for drug-induced metabolic changes. Fourth, we purpose-
fully excluded patients with defined major adverse cardiovascular 
events or known high cardiovascular risk. Therefore, our findings 
might be more representative of the general epileptic population 
that would benefit from screening regarding MetS.
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city of São Paulo using IDF criterion and observed an overall 
prevalence of 36.6% of MetS (35). In its turn, Gronner et  al. 
evaluated 1,116 adults from São Carlos, a medium-size city in 
the State of Sao Paulo, using NCEP-ATPIII and IDF and observed 
an overall prevalence of 35.9 and 43.2%, respectively (36). These 
results overlap with our observations in patients with epilepsy 
and suggest that MetS is highly prevalent in Brazilian popula-
tion and that might be also true for adult patients with epilepsy 
in Brazil. At this point, we cannot conclude that MetS is more 
prevalent in patients with epilepsy, when compared with controls 
without epilepsy. However, our results might suggest that MetS 
can be highly prevalent in adult patients with epilepsy, especially 
those living in developing regions of the world, and it might have 
impact in the health conditions of these patients. Further studies 
are clearly needed to evaluate the prevalence of MetS in patients 
with epilepsy, its variability according to world region, and its 
impact in health quality of these individuals.
Our study had methodological limitations that should be 
addressed. Besides those inherent to cross-sectional studies, 
the population characteristics hinder the applicability of our 
conclusions to youngsters and to those who already had their 
first atherothrombotic event. The absence of a control group also 
limits generalization of our findings and forbid any speculation 
how MetS might differ between epileptic and healthy subjects. 
We cannot firmly exclude that differences in etiologic evaluation 
could have led to some misclassification. Newer AEDs were 
underrepresented in out sample. Insulin kinetics parameters, as 
basal insulin levels and HOMA-IR, were not assessed. Diabetes 
was not exhaustively screened in all patients, a situation that may 
have changed since the recommendations for using HBA1C in 
routine practice (23). Finally, reference center selection bias and 
the lack of a control group preclude a definitive conclusion that 
all adult patients with epilepsy are at increased risk for MetS. Said 
that, it is worthwhile to mention that our work aimed primarily 
at providing answers for implementing future actions in clinical 
grounds. In that matter, it was not only successful but also the first 
study to provide a structured comparison of MetS criteria in the 
very special population of patients with epilepsy.
cOnclUsiOn
Our study was not adequate to access the real prevalence of MetS 
in all adult patients with epilepsy. As consequence, our data do not 
provide sufficient evidence to support the general incorporation of 
protocols for evaluating MetS in patients with epilepsy. However, 
we observed a higher prevalence of MetS and cardiovascular risk, 
irrespective of VPA use, in our cohort. Moreover, our study might 
suggest that harmonized or IDF criteria could present better sen-
sitivity/specificity for evaluating these patients. However, further 
studies with large group of patients and adequate controls are nec-
essary to evaluate the real prevalence of MetS in adult patients with 
epilepsy. For now, we believe that it is reasonable to alert physicians 
about the possibility of occurrence of MetS in patients with epilepsy 
and suggest that these patients should receive adequate evalua-
tions, recommendations, and treatments. Additional prospective 
studies are necessary to confirm our preliminary observations as 
well as to broadly assess the clinical implications of our findings.
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